ERC Society for Endocrinology Archive
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Endocrine-Related Cancer 15 (2) 583 -596     DOI: 10.1677/ERC-07-0271
Copyright © 2008 by the Society for Endocrinology
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Florio, T.
Right arrow Articles by Jaquet, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Florio, T.
Right arrow Articles by Jaquet, P.

Efficacy of a dopamine–somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study

 Tullio Florio1, Federica Barbieri1, Renato Spaziante2, Gianluigi Zona2, Leo J Hofland3, Peter M van Koetsveld3, Richard A Feelders3, Günter K Stalla4, Marily Theodoropoulou4, Michael D Culler5, Jesse Dong5, John E Taylor5, Jacques-Pierre Moreau5, Alexandru Saveanu6, Ginette Gunz6, Henry Dufour6 and Philippe Jaquet6

Departments of1 Oncology, Biology and Genetics2 Neurology, Ophthalmology and Genetics, University of Genova, Viale Benedetto XV, 2, 16132 Genova, Italy3 Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands4 Department of Endocrinology, Max Planck Institute of Psychiatry, Munich, Germany5 IPSEN, Milford, Massachusetts 01757, USA6 Departments of Endocrinology, Neurosurgery, University of Mediterranea, Marseilles, France

(Correspondence should be addressed to T Florio; Email: tullio.florio{at}unige.it)


   Abstract
Top
 Abstract
Introduction
 Patients and methods
 Results
 Discussion
 Disclosure
 References
 
Dopamine D2 and somatostatin receptors (sstrs) were reported to affect non-functioning pituitary adenoma (NFPA) proliferation in vitro. However, the reported results differ according to the experimental conditions used. We established an experimental protocol allowing reproducible evaluation of NFPA cell proliferation in vitro, to test and compare the antiproliferative effects of dopamine and somatostatin analogs (alone or in combination) with the activity of the dopamine–somatostatin chimeric molecule BIM-23A760. The protocol was utilized by four independent laboratories, studying 38 fibroblast-deprived NFPA cell cultures. Cells were characterized for GH, POMC, sstr1–sstr5, total dopamine D2 receptor (D2R) (in all cases), and D2 receptor long and short isoforms (in 15 out of 38 cases) mRNA expression and for {alpha}-subunit, LH, and FSH release. D2R, sstr3, and sstr2 mRNAs were consistently observed, with the dominant expression of D2R (2.9±2.6 copy/copy β-glucuronidase; mean±S.E.M.), when compared with sstr3 and sstr2 (0.6±1.0 and 0.3±0.6 respectively). BIM-23A760, a molecule with high affinity for D2R and sstr2, significantly inhibited [3H]thymidine incorporation in 23 out of 38 (60%) NFPA cultures (EC50=1.2 pM and Emax=–33.6±3.7%). BIM-23A760 effects were similar to those induced by the selective D2R agonist cabergoline that showed a statistically significant inhibition in 18 out of 27 tumors (compared with a significant inhibition obtained in 17 out of 27 tumors using BIM-23A760, in the same subgroup of adenomas analyzed), while octreotide was effective in 13 out of 27 cases. In conclusion, superimposable data generated in four independent laboratories using a standardized protocol demonstrate that, in vitro, chimeric dopamine/sstr agonists are effective in inhibiting cell proliferation in two-thirds of NFPAs.


   Introduction
Top
 Abstract
 Introduction
Patients and methods
 Results
 Discussion
 Disclosure
 References
 
Clinically, human non-functioning pituitary adenomas (NFPAs) represent about one-third of pituitary tumors. Such benign tumors grow slowly and are diagnosed late as macroadenomas, producing tumoral symptoms (headaches and visual field defects, due to compression of the optic chiasm) and partial or panhypopituitarism. Lateral tumor growth invading the cavernous sinuses occurs frequently as well. By immunohistochemical techniques or by culture studies most of these adenomas were shown to secrete small amounts of either gonadotropins or their subunits. In few rare cases, they may represent silent corticotroph or somatotroph adenomas. Based on ultrastructural characteristics, null cell adenomas and oncocytomas represent the less differentiated tumors containing very few cytoplasmic organelles involved in hormone secretion (see Greenman & Melmed 1996, Chanson & Brochier 2005, Kontogeorgos 2005 for review). Transsphenoidal neurosurgery is the first-line treatment for these tumors, but it is often incomplete in invasive adenomas, particularly in those extending into the cavernous sinuses.

For these reasons adjuvant antitumor pharmacological treatments could be of importance, to prevent the regrowth of tumor remnant, after partial surgical removal of the adenoma. Despite the identification of dopamine (Bevan et al. 1992) and somatostatin receptors (sstrs; Greenman & Melmed 1994a,b), minor tumor shrinkage, if any, was reported in a small series of patients with NFPAs treated with either bromocriptine or octreotide (Bevan et al. 1992, de Bruin et al. 1992, Katznelson et al. 1992). A new class of chimeric drugs, combining somatostatin and dopamine receptor binding activity in the same molecule, was recently shown to be more effective than each single agonist in the growth hormone (GH)-secreting adenomas, partially responding to octreotide (Jaquet et al. 2005). Thus, we investigated the efficacy of one of these dopamine–somatostatin chimeric compounds, namely BIM-23A760, in inhibiting [3H]thymidine incorporation in short-term culture studies from a large series of NFPAs. The adenomas were characterized quantifying the expression level of the different sstr subtypes (sstr1–sstr5), dopamine D2 receptor (D2R) and its isoforms (D2Rlong and D2Rshort) mRNA, using real-time PCR on isolated adenoma cells, in culture. The functional role of these receptors was analyzed using [3H]thymidine incorporation assay in the presence of various concentrations of the somatostatin analog, octreotide, the dopamine agonist, cabergoline, and the somatostatin/dopamine chimeric molecule, BIM-23A760, in cell cultures from 38 consecutive pituitary tumors studied in four different centers.

The main objective was to determine whether the chimeric molecule, BIM-23A760, can achieve a better acute control of cell growth when compared with the individual dopamine and/or somatostatin analogs.


   Patients and methods
Top
 Abstract
 Introduction
 Patients and methods
Results
 Discussion
 Disclosure
 References
 
Patients

Among the 38 cases, 25 patients were males and 13 females. Their age ranged from 22 to 77 years, with an average of 53.1±13.2 years (mean±S.D). All presented with macroadenomas, either non-invasive (n=15), with suprasellar extensions in all but one case, or with intrasphenoidal or intracavernous extensions (n=23). In most patients, luteinizing hormone (LH), follicle-stimulating hormone (FSH), and {alpha}-subunit plasma levels were low or in the normal range (data not shown). In all the cases, endocrinological investigations ruled out any GH or adrenocorticotrophin (ACTH) hypersecretion. A mild hyperprolactinemia (PRL plasma levels: 24–35 ng/ml) was noticed in four subjects. Analysis of pituitary function, using different provocative tests, revealed normal activity, partial pituitary deficiency, and panhypopituitarism in 20, 10, and 8 patients respectively. Tumor and patient characteristics are described in Table 1. These studies were approved by the Ethics Committee of each individual institution.


View this table:
[in this window]
[in a new window]

  		Table 1 Individual clinical and pathological characteristics of the patients and tumors

 
Pharmacological compounds

The somatostatin analog octreotide was a kind gift of Novartis (Novartis AG). It is essentially directed toward the sstr2 and sstr5 subtypes and, at a lesser degree, the sstr3 subtype (IC50: 0.6, 7.0 and 34 nM respectively; Jaquet et al. 2005). The D2R agonist cabergoline (IC50: 25 nM) was a gift from Dr A Harris (Pharmacia Upjohn). The chimeric compound, BIM-23A760, was provided by Biomeasure Inc./IPSEN (Milford, MA, USA). It shows very high affinity to sstr2 (IC50: 0.03 nM), low affinity to sstr5 (IC50: 42 nM) and no affinity to sstr3 (IC50: 160 nM) when compared with somatostatin, and approximately equal affinity to D2R as cabergoline (IC50: 15 nM; Jaquet et al. 2005). The somatostatin analogs were dissolved as 1 mM solutions in 0.01 M acetic acid containing 0.1% purified BSA (Life Technologies Inc). Cabergoline was prepared as 1 mM solution in 0.01 M acetic acid and 70% ethanol. L-Sulpiride was purchased from Sigma–Aldrich and prepared as a 1 mM solution in ethanol. All compounds were stored at –80 °C. For each experiment, a fresh aliquot of each compound was diluted with PBS supplemented with 1% BSA.

Primary culture of pituitary adenoma cells and [3H]thymidine incorporation assay

After surgery, tumor specimens were placed in complete Dulbecco's minimum Eagle's culture medium (DME medium), supplemented with 10% heat-inactivated fetal calf serum (FCS) and antibiotics, and dissociated by mechanic and enzymatic methods according to the standard protocols. To obtain adenoma cell preparations deprived of rapidly dividing fibroblasts, dispersed cells were filtered through a magnetic bead column coated with antifibroblast antibodies (Miltenyi Biotec, Paris, France), according to the manufacturer's specifications. The resulting cells were plated in 48-well culture plates at a density of 105 cells/well in 0.5 ml of the complete DME medium. Depending on the available tissue, 3–70x106 isolated cells/adenoma were obtained. After 3 days, the culture medium was collected for hormone determination, and replaced by DME medium containing D-valine (Metachem, London, UK), 105 U/l penicillin, 1% FCS. The use of D-valine in the culture medium suppresses the proliferation of any remaining contaminating fibroblasts (Renner et al. 1994). Test substances were added at the appropriate final concentrations for 24 h in the presence of [3H]thymidine (2 µCi/ml; Amersham) and phorbol myristate acetate (PMA, 100 nM; Sigma–Aldrich). At the end of the incubation with [3H]thymidine, cells were washed, harvested, extracted, and counted in a scintillation counter in order to determine [3H]thymidine uptake, according to the standard protocols used by the individual laboratories (Koper et al. 1990, Florio et al. 1992, Renner et al. 1994, Ferone et al. 2005).

In these experiments, octreotide, cabergoline, the combination of the two and the chimeric molecule, BIM-23A760, were tested at predetermined maximal concentrations (10–9 M), or at concentrations ranging from 10–12 to 10–9 M, in order to provide dose–response relationship and to determine the EC50 for each compound with regard to the inhibition of [3H]thymidine incorporation. In selected experiments, the D2R antagonist, L-sulpiride (10–5 M), was added in combination with either cabergoline, octreotide or BIM-23A760, in order to dissect the specific role of D2R and sstr subtypes in BIM-23A760 effects. Each measurement was performed in quadruplicate. In addition, the pituitary fibroblasts, trapped by the antifibroblast antibody-coated beads were eluted from the column and expanded by multiple passages in 10% FCS–DME medium, without D-valine, in culture dishes, in order to obtain purified fibroblasts originating from the tumoral tissue. In such preparations, no LH, FSH, or PRL could be measured in the culture medium. These fibroblasts were used for both mRNA quantification and [3H]thymidine incorporation studies.

mRNA analysis

mRNA analysis was performed at University of Mediterranean (Marseilles, France) on cell samples derived from all the 38 tumors. After adenoma cell isolation, two 2.5x105 cell aliquots were resuspended in RLT lysis buffer (Quiagen) and stored at –80 °C until quantitative PCR characterization. One aliquot was used to quantify mRNA expression of D2R and sstr1–sstr5. In 15 tumors, the detection of the D2R isoforms, D2Rlong and D2Rshort, was also assessed. The second aliquot was used for quantification of FSH, LH, {alpha}-subunit, GH, and pro-opiomelanocortin (POMC) mRNA expression, in order to characterize the different NFPAs and to screen for potential contamination of the tumor cells by adjacent pituitary non-tumoral cells. From each cell sample, 1–1.5 µg RNA was obtained, of which 1 µg of total RNA was used for cDNA synthesis, as previously described (Saveanu et al. 2002). Expression of D2R and the sstr subtype mRNA was determined by real-time quantitative PCR, using primer and probes as previously described (Saveanu et al. 2002). Primers and probe for D2Rlong (TaqMan Gene Expression Assay Hs01024460_m1) were purchased from Applied Biosystems (Foster City, CA, USA). Primers and probe for D2Rshort were the following: forward, 5'-TTGTCACCCTGCTGGTCTAC-3'; reverse, 5'-GGAGAGCATCTCCATCTCCA-3'; LNA probe: 5'-HEX-CTCCACTA6A8GA8GGCTGCCCG-TAMRA-3'. TaqMan Gold nuclease assay was used (Perkin–Elmer, Foster City, CA, USA). The amplification reactions were carried out on an ABI PRISM 7700 sequence Detection System (Perkin–Elmer), according to the manufacturer's protocol. For quantification of the results, the D2R and sstr subtype mRNA levels were normalized in the same reaction to the β-glucuronidase (β-Gus) mRNA level. For each measurement, two independent RT-PCR analyses were performed.

Immunohistochemical methods

Immunohistochemical staining for LH, FSH, and {alpha}-subunit was performed on formalin-fixed paraffin embedded sections in the individual centers according to the standard protocols. The results of immunohistochemical analysis were obtained by counting the percentage of positive cells for the respective hormones by two persons and scored as: 0, no immunoreactivity detected; +, <20% of the cells; ++, >20<50%;+++, >50%.

Hormone assays

Hormone content was analyzed in 3-day culture medium from 13 out of 38 cell cultures and performed at Erasmus Medical Center (Rotterdam, The Netherlands) for all the samples analyzed. The following assays were used: {alpha}-subunit by IRMA from Immunotech SAS (Marseille, France), intra-assay coefficient of variation (CV) 5.4%, inter-assay CV 8.8%, results in IU/l; ACTH by solid phase, two-site sequential chemiluminescent immunometric assay (ICMA, Diagnostic Products Corporation, DPC, Los Angeles, CA, USA), intra-assay CV 7.5%, inter-assay CV 8.4%, results in pg/ml; LH by ICMA from DPC, intra-assay CV 4.8%, inter-assay CV 10.7%, results in IU/l; FSH by ICMA from DPC, intra-assay CV 3.4%, inter-assay CV 5.4%, results in IU/l; PRL by ICMA from DPC, intra-assay CV 6.2%, inter-assay CV 8.5%, results in IU/l; and GH by ICMA from DPC, intra-assay CV 3.7%, inter-assay CV 5.7%, results in µg/l.

Statistical analysis

The results are expressed as mean±S.E.M. Statistical significance was determined by ANOVA followed by Newman–Keuls test. P<0.05 was considered statistically significant.


   Results
Top
 Abstract
 Introduction
 Patients and methods
 Results
Discussion
 Disclosure
 References
 
Characteristics of the tumors

The immunohistochemical analysis of sections from all the tumors studied is reported in Table 1. Null cell tumors, not showing granules positive for {alpha}-subunit, FSH, or LH, represented 18% of the cases, while adenoma cells were positively stained by anti-FSH, anti-LH, and anti-{alpha}-subunit antibodies in 66, 43, and 38% of the tumors respectively (Table 1). None of these adenomas exhibited ACTH- or GH-positive cells as observed in silent somatotroph or corticotroph adenomas. In six tumor fragments, foci of normal pituitary tissue were noted within the adenomatous fragments (Table 1).

Characterization of the NFPA cell cultures

Hormone release in the medium was monitored for a 72 h period under basal conditions in 13 out of 38 cell cultures (Table 2). In 10 out of 13 cases, adenoma cells released FSH and LH in variable amounts. In 4 out of 13 tumor cell cultures, the release of FSH and LH was low (<1 IU/medium) and three tumors (no. 2, 14, and 17) secreted higher amounts of all the hormones tested (LH, FSH, and {alpha}-subunit). The {alpha}-subunit was detectable in five cases (39%). In three tumors no hormone release was detected.


View this table:
[in this window]
[in a new window]

  		Table 2 In vitro hormone release in the culture medium from dispersed non-functioning human pituitary adenoma (NFPA) cells

 
In order to check the possible contamination of dispersed adenoma cells by normal anterior pituitary tissue, the transcripts for GH, PRL, and POMC were quantified in all the adenoma cell samples. The GH, PRL, and POMC mRNA expression levels were <1% in 35 out of 38 measurements when compared with the mean mRNA levels measured in series of ACTH-, PRL-, and GH-secreting adenomas. In the remaining three tumor cell cultures, the level of GH (n=2) or POMC (n=2) mRNA expression varied from 1.2 to 6.3% indicating a slight contamination with somatotroph or corticotroph cells, most likely originating from normal pituitary, as already evidenced by immunohistochemical analysis of sections from the same tumors (Table 1).

D2R and sstr subtype mRNA expression in NFPA cell cultures

D2R, sstr2, or sstr3 mRNAs were detected in cells isolated from most of the tumors, but at very different levels of expression (Fig. 1a). D2R, sstr2, and sstr3 mean mRNA levels were 2.9±2.6, 0.3±0.6, and 0.6±1.0 copy/copy β-Gus respectively. With the exception of only three cases, D2R mRNA expression was predominant over sstr. Under individual analysis, 7 out of 38 tumors lacked sstr2 mRNA, 8 out of 38 tumors lacked sstr3 mRNA, and all the tumors expressed D2R.


Figure 1
View larger version (18K):
[in this window]
[in a new window]

  		Figure 1 D2R and sstr mRNA quantification in 38 NFPA cell cultures. The mRNA analysis was performed on 2.5x105 isolated NFPA cells stored at –80 °C until quantitative PCR characterization. To obtain purified NFPA cells, after dispersion the cells were filtered through a column of antifibroblast antibodies coated on magnetic beads. (a) sstr and D2R mRNAs from 38 adenoma cell cultures (mean±S.E.M). (b) The sstr and D2R mRNAs from 5x105 fibroblasts, eluted from the magnetic bead column and expanded in culture (mean±S.E.M.; n=2). Results are expressed as copy/copy of the β-glucuronidase housekeeping gene (β-Gus).

 
In this series, only one NFPA showed low level expression of sstr1 mRNA (0.06±0.02 copy/copy β-Gus), and only four tumors showed a weak sstr5 expression (0.03±0.14 copy/copy β-Gus). Individual values of mRNA expression for each tumor are presented in Table 3.


View this table:
[in this window]
[in a new window]

  		Table 3 The mRNA levels for somatostatin receptor 2 (sstr2), sstr3, and dopamine D2 receptor (D2R) (copy/copy β-glucuronidase (β-Gus)), D2Rlong/D2Rshort mRNA expression ratio and [3H]thymidine uptake (percentage of inhibition of phorbol myristate acetate (PMA)-treated cells) in dispersed cells from individual non-functioning human pituitary adenomas (NFPAs)

 
In 15 NFPAs, mRNAs for the two predominant D2R isoforms (long and short) were quantified. In two cases (NFPA no. 7 and 38), D2Rshort isoform was not detected. In the other 13 cases, mRNAs for both variants were identified although D2Rlong was the predominant isoform (95.4±4.7% of total D2R mRNA), as shown in all the individual cases in Table 3.

The sstr subtype and D2R mRNA expression was also measured in two subpopulations of purified human pituitary-derived fibroblasts. As shown in Fig. 1b, only sstr1 mRNA was detected (0.4±0.1 copy/copy β-Gus) in these cell cultures. According to the tumors, 12–38% of the dispersed adenoma cells were trapped by the antifibroblast antibodies coated on the magnetic beads, which retain fibroblasts and non-viable cells.

Maximal effects of octreotide, cabergoline, and BIM-23A760 on [3H]thymidine incorporation

Prior to the primary studies, we compared the yield of [3H]thymidine incorporation in the absence or the presence of PMA (100 nM). As shown in four different experiments (Table 4), in the absence of PMA, BIM-23A760 was unable to affect [3H]thymidine incorporation. When the DNA synthesis was activated by PMA, a –20 to –33% inhibition of [3H]thymidine incorporation was observed in BIM-23A760-treated cells derived from the same tumors. Consequently, we performed all the following experiments in the presence of PMA stimulation.


View this table:
[in this window]
[in a new window]

  		Table 4 Effects of phorbol myristate acetate (PMA) treatment on BIM-23A760 (1 nM) inhibition of [3H]thymidine uptake in dispersed non-functioning human pituitary adenoma (NFPA) cells

 
Preliminary experiments were performed to evaluate the efficacy of different BIM-23A760 concentrations. The dose–response curve of BIM-23A760, used at concentrations up to 100 nM, demonstrated that its maximal inhibitory effect on [3H]thymidine incorporation was obtained at 1 nM (data not shown). Thus, this concentration was selected as the highest BIM-23A760 concentration in the following experiments.

The efficacy of BIM-23A760 to inhibit PMA-stimulated DNA synthesis was analyzed in 38 individual NFPA cultures. In 23 out of 38 (60%) cell cultures, BIM-23A760 (1 nM) produced a significant (P<0.05) inhibition of [3H]thymidine incorporation (–33.6±3.7%). In the other 15 cases, non-statistically significant variations of the percentage of [3H]thymidine incorporation versus respective controls occurred (ranging from –7.8 to +17.4%), as shown in Table 3.

To correlate the responsiveness of the NFPAs studied with their receptor expression pattern, we analyzed whether differences in receptor mRNA content occurred in responsive tumors versus the non-responsive ones. In the 23 tumors sensitive to BIM-23A760 (Table 3, tumors no. 1–23), the mean levels of D2R, sstr2, and sstr3 mRNA expression were 2.19±0.49, 0.36±0.15, and 0.54±0.25 copy/copy β-Gus respectively, when compared with those measured in tumors resistant to BIM-23A760 (Table 3, tumors no. 24–38), in which the following mean values were detected: 3.92±0.69, 0.26±0.10, and 0.61±0.21 copy/copy β-Gus.

The sstr2 and sstr3 expression was similar in both groups (P<0.4 and <0.3 respectively). Surprisingly, D2R mRNA expression was significantly higher in the group of tumors resistant to BIM-23A760 (P<0.02). However, no differences in the expression level of the D2Rlong and D2Rshort isoforms was observed in a subgroup of NFPAs responsive (n=7) and non responsive (n=8) to BIM-23A760 (Table 3).

We also compared the biological and clinical characteristics of BIM-23A760 responsive versus non-responsive NFPAs. However, as far as differentiation status (i.e., percentage of null cell tumors), aggressive behavior in vivo (invasive versus enclosed tumors), or tumor-dependent panhypopituitarism (Table 1) are concerned, we did not observe statistically significant differences between the two groups of tumors.

BIM-23A760 maximal effects were also compared with those induced by the selective D2R and sstr2 agonists cabergoline and octreotide (1 nM), in a subgroup (n=27) of these tumors. In these NFPAs, BIM-23A760 caused a statistically significant inhibition of [3H]thymidine incorporation in 17 out of 27 tumors (63%), when compared with cabergoline that was effective in 18 out of 27 tumors (66%). Octreotide caused a comparable effect in 13 out of 27 tumors (48%) and the combined treatment octreotide+cabergoline was effective in 12 out of 22 tumors (54%). In the responsive NFPAs of this subgroup, octreotide, cabergoline, and the combination of the two, produced a mean maximal inhibition of [3H]thymidine incorporation, similar to that achieved with BIM-23A760 (–22, –27 and –22% respectively, versus –28% with BIM-23A760, Fig. 2b).


Figure 2
View larger version (35K):
[in this window]
[in a new window]

  		Figure 2 [3H]thymidine uptake inhibition from cell cultures of 38 NFPAs. (a) Dose–response curves to BIM-23A760 versus controls (PMA alone) in 23 NFPA cell cultures responsive to BIM-23A760 (P<0.05 in at least one BIM-23A760 concentration, open squares) in 15 cell cultures from NFPAs non-responsive to BIM-23A760 (filled squares), and in two cultures from pituitary-derived fibroblasts (stars). Results are expressed as mean±S.E.M. Each experimental measurement was performed in four independent wells. Averaging all the results, P<0.05 was observed for all the drug concentrations in the responsive NFPAs (open squares). (b) Mean maximal [3H]thymidine uptake inhibition with 10–9 M BIM-23A760, octreotide, cabergoline, or octreotide+cabergoline. The number of tumor cell cultures tested is shown in parenthesis. Results are expressed as mean±S.E.M. (c) Dose–response curves to cabergoline, octreotide, cabergoline+octreotide, and BIM-23A760 versus controls (PMA alone) in four NFPA cultures. Results are expressed as mean±S.E.M. Each experimental measurement was performed in four independent wells.

 
Dose–response of BIM-23A760, octreotide, and cabergoline on [3H]thymidine incorporation

The dose–response of BIM-23A760 (1 pM–1 nM) on [3H]thymidine incorporation was tested in all the 38 NFPAs analyzed. In 15 out of 38 tumor cultures, BIM-23A760 had no effect on [3H]thymidine incorporation at any concentration. In 23 out of 38 NFPA cell cultures, a significant (P<0.05) dose-dependent inhibition of [3H]thymidine incorporation was observed with an EC50 of 1.2 pM (Fig. 2a). The majority of the NFPAs responsive to BIM-23A760 (61%) displayed a statistically significant inhibition at low concentrations (1 and 10 pM), although proliferation of a number of tumors (9 out of 23, 39%) was significantly inhibited only at the highest BIM-23A760 concentration tested (1 nM). In control experiments using pituitary fibroblasts, BIM-23A760 (Fig. 2a), as well as cabergoline (data not shown), had no effect on [3H]thymidine uptake.

When the cell cultures derived from a group of NFPAs responsive to BIM-23A760 were treated with 1 pM–1 nM concentrations of octreotide, cabergoline, the combination of the two, and BIM-23A760, a similar dose–response curve for inhibition of [3H]thymidine uptake was obtained (n=4, Fig. 2c). The EC50s for these compounds ranged from 10 to 50 pM.

Effects of L-sulpiride co-incubation with BIM-23A760 on [3H]thymidine incorporation

To establish specific roles for D2R and sstr subtypes in BIM-23A760 inhibition of [3H]thymidine uptake in cultured NFPA cells, we measured the effects of BIM-23A760 in the presence of the selective D2R antagonist, L-sulpiride. Under these experimental conditions, L-sulpiride shifted the BIM-23A760 dose–response curve on the right, by one order of magnitude (Fig. 3a). Indeed, in the presence of L-sulpiride, BIM-23A760 had no significant effect on DNA synthesis at low concentrations (10 pM) and a reduced efficacy was observed using the higher doses (100 pM and 1 nM: –50% of the inhibitory effects obtained in control cells). As expected, L-sulpiride completely reversed the effect of cabergoline in the same tumors, and had no effect on octreotide-induced inhibition of DNA synthesis (Fig. 3b).


Figure 3
View larger version (28K):
[in this window]
[in a new window]

  		Figure 3 Effect of D2R blockade by L-sulpiride on [3H]thymidine uptake inhibition, in the presence of PMA, in five NFPA cultures equally responsive to octreotide and cabergoline. (a) Dose–response of BIM-23A760 (10 pM–1 nM) in the absence or presence of L-sulpiride (10 µM). (b) L-Sulpiride (10 µM) reversal of cabergoline (1 nM), but not octreotide (1 nM), inhibition of [3H]thymidine uptake. *P<0.05 versus respective control values.

 

   Discussion
Top
 Abstract
 Introduction
 Patients and methods
 Results
 Discussion
Disclosure
 References
 
NFPAs are slow growing tumors diagnosed late in the course of the disease by compressive symptoms caused by the macroadenomas. Surgery is the first-line treatment, as current medical therapies are mostly unsuccessful in shrinking NFPA mass. Due to the often incomplete surgical removal of these adenomas, tumor regrowth occurs in 40–52% of non-irradiated patients, according to long-term retrospective or prospective studies (Comtois et al. 1991, Gittoes et al. 1998, Greenman et al. 2003, Ferrante et al. 2006). In one prospective study, in the subgroup of patients that presented after surgery with cavernous sinus invasion or large suprasellar tumor remnants, a 70% further tumor extension was observed by repetitive magnetic resonance imaging over the subsequent 5 years (Greenman et al. 2003). In such a subgroup of invasive adenomas, medical therapy, able to prevent or slow down tumor regrowth, would be beneficial to avoid the long-term complications produced by radiotherapy. Nevertheless, the overall efficacy of the currently used somatostatin analogs to limit NFPA growth is poor. In vitro, they produce a 28–34% inhibition of FSH, LH, or {alpha}-subunit release in 28% of cases (Klibanski et al. 1991, de Bruin et al. 1992, Hofland et al. 1997) and the efficacy of octreotide in inducing tumor shrinkage in vivo is even less impressive and poorly conclusive. Among 48 patients with NFPAs, a >20% reduction in the maximal tumor diameter was reported in seven cases (Plockinger et al. 1994, Warnet et al. 1997). Medical treatment, using the dopamine agonist bromocriptine, also shows efficacy in reducing tumor mass in few patients with NFPAs (van Schaardenburg et al. 1989). More recently, treatment with the dopamine D2R superagonist cabergoline provided variable results (Colao et al. 2000, Lohmann et al. 2001, Pivonello et al. 2004) that were eventually linked to differential expression of the dopamine D2Rshort isoform. Up to now, there has been only one convincing report that showed prospectively a decrease or a stabilization of tumor mass in 18 out of 20 patients presenting with a tumor remnant after surgery, followed by treatment with bromocriptine over a mean follow-up period of 41 months (Greenman et al. 2005).

In this study, we investigated the antiproliferative effect of a novel chimeric compound, BIM-23A760, on human NFPA cell short-term culture experiments, under PMA-stimulated conditions. Human pituitary adenoma cells, in primary in vitro cultures, have almost lost their capability of duplication, and, even in vivo, NFPAs are considered as slow growing tumors (Dekkers et al. 2007). Indeed, unlike previous papers, where in vitro proliferation of human pituitary adenoma cells was reported (up to 3 days in Zatelli et al. (2004) and Batista et al. (2006)), no significant cell growth was observed in our experiments. In previous studies from our group (Florio et al. 1999) basal [3H]thymidine uptake was relatively low in most adenomas and, on the average, somatostatin treatment did not result in a significant reduction of basal DNA synthesis in 9 out of 11 non-functioning adenomas. Similarly, in another study (Renner et al. 1994), we observed suppression of basal cell proliferation by bromocriptine in only three out of nine adenoma cell cultures. For these reasons, in the present protocol, we triggered the activation of the PKC pathway by PMA previously shown to induce a significant increase in DNA synthesis in most of the tumors and to restore the inhibitory effect of somatostatin on DNA synthesis (Renner et al. 1994, Florio et al. 1999). Indeed, although very few NFPA cells actually divide in vitro, they still possess the needed machinery to initiate DNA replication, an event easily detectable in the [3H]thymidine uptake assay. PMA is a known tumor promoter that directly activates PKC and, indirectly, the ERK1/2 MAP kinase cascade (Kolch et al. 1993). ERK1/2 is one of the main regulators of cell proliferation being responsible, among other effects for the synthesis of cyclin D (Cheng et al. 1998), a prerequisite for cells to enter the S-phase of the cell cycle. Importantly, a PKC-dependent ERK1/2 activation was reported to increase mitogenic activity (i.e., cyclin D1 expression) but not hormonal secretion from in vitro cultures of both human GH-secreting pituitary adenomas and NFPA (Lania et al. 2003) On the other hand, in NFPA cell cultures, PKC inhibition by calphostin C is the main intracellular signal to downregulate ERK1/2 activation (Mantovani et al. 2005). Thus, we propose that, in vitro, the presence of PMA can surrogate growth factors likely present in vivo to support NFPA cell duplication. More importantly, in these experimental conditions, the effects of both somatostatin and dopamine analogs can be more clearly detected, since the PMA-activated tentative of entering the cell cycle can effectively be inhibited by blocking ERK1/2 through the activation of both D2R and sstr. In fact, it is now well accepted that specific phosphotyrosine phosphatases, activated by both somatostatin (Pan et al. 1992, Lopez et al. 1997) and dopamine (Florio et al. 1992) receptors, can interfere with ERK1/2 activation to prevent cell proliferation (Florio et al. 2001, Massa et al. 2004).

Prior to the pharmacology studies, we measured the expression of both sstr and D2R mRNAs in purified cultured tumor cells. Previous qualitative analyses about sstr subtypes expressed by tumor specimens from non-functioning and gonadotroph human pituitary adenomas revealed mainly sstr3 and sstr2 expression (Greenman & Melmed 1994a,b, Nielsen et al. 2001, Reubi et al. 2001). In a recent quantitative analysis of sstr gene expression, sstr3 mRNA was identified at the highest level, followed by sstr2. The sstr1, sstr4, and sstr5 mRNAs were detected, at low levels, only in few cases (Taboada et al. 2007). In this study, using isolated NFPA cells, a predominant sstr3/sstr2 pattern of expression in NFPAs was also observed. This contrasts with previous reports in which sstr1, sstr2, sstr3, and sstr5 are equally expressed in the majority of the tumors analyzed by either PCR (Florio et al. 1999) or immunohistochemistry (Pawlikowski et al. 2003). In another study, a selected subgroup of 12 out of 71 NFPAs (16.9%) expressing {alpha}-subunit mRNA and secreting {alpha}-subunit in vitro, was reported to express mRNA for sstr1, sstr2, and sstr5, as determined by RT-PCR (Zatelli et al. 2004). Interestingly, in these adenoma cells, {alpha}-subunit secretion was inhibited by sstr1- and sstr2-specific agonists, while the cell viability was reduced by an sstr1-selective compound. Such discrepancies between the different studies can be, at least partly, explained by the heterogeneity of the NFPAs populations analyzed. For example, silent somatotroph or corticotroph adenomas, not observed in our series although included in the NFPA classification, express sstr1, sstr2, and/or sstr5 (Jaquet et al. 2000, Hofland et al. 2005). Furthermore, plurihormonal gonadotroph–lactotroph tumors suppress their hormone secretion when exposed to dopamine or somatostatin analogs in vivo and in cell culture studies, in accordance with the high expression of sstr2, sstr3, and sstr5 (Saveanu et al. 2001). This study also differs from previous reports because adenoma cells were stripped of fibroblasts, which, as previously shown in sarcoma fibroblasts (Reubi et al. 2001) and confirmed in fibroblasts isolated from pituitary adenomas in our study, only expressed sstr1 transcripts. The sstr1 was faintly expressed in only 1 out of 38 fibroblast-free NFPA cell culture. The sstr5 mRNA was detected at very low levels (0.03±0.14 copy/copy β-Gus) in 4 out of 38 tumors, which also expressed POMC and GH mRNAs, suggesting the likely contamination by pituitary cells of non-tumoral origin.

This study compared, for the first time, the level of expression of both sstr and D2R mRNAs in NFPAs. All the tumors expressed D2R mRNA at a mean level of expression higher than those observed for sstr3 or sstr2 in most of the individual adenoma cell cultures. Nevertheless, D2R expression observed in NFPAs was 30-fold less than the D2R mRNA level measured in a series of PRL-secreting adenomas (Jaquet et al. 1999).

Importantly, we show that the chimeric somatostatin/dopamine agonist BIM-23A760 significantly inhibited [3H]thymidine uptake in ~60% of the NFPAs treated. A significant inhibition only at the highest concentration tested (1 nM) was reached in 39% of the responsive tumors while, in the other cases, 1–10 pM BIM-23A760 was sufficient to induce a statistically significant inhibition of DNA synthesis. In agreement with the highest expression of D2R, this effect was mainly dependent on D2R activation since it was greatly reduced (although not completely abolished) by the D2R antagonist, L-sulpiride. Similar results were reported by Gruszka et al. (2006) which showed comparable antiproliferative effects in six out of ten NFPA cultures using either the D2R agonist bromocriptine, sstr1, sstr2, and sstr5 selective agonists or another dopamine/somatostatin chimeric compound, BIM-23A387, although the most effective was bromocriptine.

A crucial issue in the analysis of these results was the identification of possible molecular determinants of NFPA sensitivity to sstr/D2R chimeric agonist. To this end, we compared the biological characteristics of BIM-23A760 responsive versus non-responsive NFPAs. However, no statistically significant differences were found between the two groups considering all the parameters tested (differentiation status defined by the percentage of null cell tumors, in vivo aggressive behavior including invasive versus enclosed tumors or tumor-dependent panhypopituitarism, etc).

In our study, the levels of expression of sstr was not correlated with the pharmacological responses to either octreotide, cabergoline, or BIM-23A760, while non-responsive NFPAs expressed higher D2R mRNA level than the responsive ones (P<0.02). Such an absence of correlation is in contrast with the significant relationship previously reported between the expression of sstr2 and the degree of suppression of GH secretion, observed in GH-secreting tumors (Jaquet et al. 2000, Hofland et al. 2004, Taboada et al. 2007) or D2R mRNA level and the response to dopamine analogs in prolactinomas (Pellegrini et al. 1989). The lack of correlation between D2R mRNA expression and control of [3H]thymidine incorporation is surprising. Previous studies associated the D2Rshort isoform expression with a better response to long-term cabergoline treatment, in terms of inhibition of {alpha}-subunit secretion and tumor shrinkage (Renner et al. 1998, Pivonello et al. 2004). Indeed, from a biochemical point of view, the differences in the antiproliferative effects elicited by the two D2R isoforms are related to the capability to inhibit the ERK1/2 pathway, an effect that was exerted only by the short variant (Iaccarino et al. 2002, Van Ham et al. 2007). We analyzed 15 NFPAs for the expression of the two D2R variants. The D2Rlong isoform was largely predominant in all analyzed cases, as previously outlined (Renner et al. 1998, Pivonello et al. 2007), but again, no correlation between the D2Rshort isoform mRNA expression levels and sensitivity to BIM-23A760 was found (Table 3). In agreement with our in vitro data, in vivo observations looking for a predictive role of [123I]epidepride D2R imaging showed the absence of correlation between the receptor-binding levels and the long-term efficacy of dopamine agonist treatments in terms of tumor mass stabilization or shrinkage (de Herder et al. 2006). Consequently, we cannot provide an answer to the question why approximately one-third of the NFPA studied are insensitive to the chimeric compound. However, this phenomenon, rather than to be dependent on BIM-23A760 characteristics, seems to be related to the biological features of individual NFPAs, since similar results were observed using the selective D2R and sstr agonists, cabergoline, and octreotide.

Our results did not show any statistically significant difference between the various treatments with regard to maximal inhibition, EC50 or percentage of responsive tumors. Again, such an absence of synergistic effects seems to be an event related to individual characteristics of the NFPAs analyzed. Indeed, while no synergism was recently observed in GH and prolactin-secreting rat pituitary cell lines (Gruszka et al. 2007), a different response was observed in human GH-secreting adenomas in which the simultaneous activation of sstr and D2R significantly enhanced their antisecretory and antiproliferative responses (Jaquet et al. 2005). Interestingly, a different sstr expression pattern was observed in tumors from acromegalic patients that show significantly higher sstr5 mRNA levels than NFPAs, which, instead, display higher levels of sstr3.

As far as the molecular mechanism of BIM-23A760 effects is concerned, it could differ according to cell types. In this respect, it is relevant to discuss the recent demonstration that a different pattern of sstr2–D2R heterodimerization occurs in cultured striatal neurons versus chinese hamster ovary (CHO) or human embryonic kidney (HEK)293 cells transfected with both receptors (Baragli et al. 2007). In these neurons, naturally co-expressing sstr2 and D2R, constitutive sstr2–D2R heterodimers were detected and heterodimerization was further promoted only by dopamine treatment. Conversely, in CHO- or HEK293-transfected cells, dopamine and somatostatin agonists synergistically promoted receptor heterodimerization, which was absent in basal conditions. These observations suggest that the different pattern of receptor association is the constitutive key regulator of cell responses to multiple receptor ligands, like BIM-23A760. Thus, although it was proposed that heterodimerization of dopamine and sstrs may result in an increased biological response in some cellular environments (Rocheville et al. 2000), this event does not seem to participate in the antiproliferative activity of BIM-23A760 in NFPA cell cultures. Thus, as far as NFPAs are concerned, the main interest of an sstr2/D2R molecule could lie in its ability to elicit responses in those tumors lacking or expressing very low levels of one of these receptors.

In conclusion, our short-term in vitro study shows that BIM-23A760 is able to inhibit [3H]thymidine incorporation in similar dose-related manner than octreotide and cabergoline. Despite the absence of synergism between the combination of both drugs or activating sstr and D2R using the somatostatin/dopamine chimeric molecule, BIM-23A760, the latter compound was able to inhibit cell proliferation in ~60% of the tumors in culture. A long-term clinical trial, as defined previously (Greenman et al. 2005), will be necessary to confirm the possible therapeutic utility of such a compound.


   Disclosure
Top
 Abstract
 Introduction
 Patients and methods
 Results
 Discussion
 Disclosure
References
 
This work was partially funded by a grant from IPSEN Inc. M D C, J D, J E T, and J-P M are employees of IPSEN Inc.


   References
Top
 Abstract
 Introduction
 Patients and methods
 Results
 Discussion
 Disclosure
 References
 
Baragli A, Alturaihi H, Watt HL, Abdallah A & Kumar U 2007 Heterooligomerization of human dopamine receptor 2 and somatostatin receptor 2 co-immunoprecipitation and fluorescence resonance energy transfer analysis. Cell Signalling 19 2304–2316.[CrossRef][Web of Science][Medline]

Batista DL, Zhang X, Gejman R, Ansell PJ, Zhou Y, Johnson SA, Swearingen B, Hedley-Whyte ET, Stratakis CA & Klibanski A 2006 The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 91 4482–4488.[Abstract/Free Full Text]

Bevan JS, Webster J, Burke CW & Scanlon MF 1992 Dopamine agonists and pituitary tumor shrinkage. Endocrine Reviews 13 220–240.[Abstract/Free Full Text]

de Bruin TW, Kwekkeboom DJ, Van't Verlaat JW, Reubi JC, Krenning EP, Lamberts SW & Croughs RJ 1992 Clinically nonfunctioning pituitary adenoma and octreotide response to long term high dose treatment, and studies in vitro. Journal of Clinical Endocrinology and Metabolism 75 1310–1317.[Abstract]

Chanson P & Brochier S 2005 Non-functioning pituitary adenomas. Journal of Endocrinological Investigation 28 93–99.[Medline]

Cheng M, Sexl V, Sherr CJ & Roussel MF 1998 Assembly of cyclin D-dependent kinase and titration of p27Kip1 regulated by mitogen-activated protein kinase kinase (MEK1). PNAS 95 1091–1096.[Abstract/Free Full Text]

Colao A, Ferone D, Lastoria S, Cerbone G, Di Sarno A, Di Somma C, Lucci R & Lombardi G 2000 Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide. Clinical Endocrinology 52 437–445.[CrossRef][Medline]

Comtois R, Beauregard H, Somma M, Serri O, Aris-Jilwan N & Hardy J 1991 The clinical and endocrine outcome to trans-sphenoidal microsurgery of nonsecreting pituitary adenomas. Cancer 68 860–866.

Dekkers OM, Hammer S, de Keizer RJ, Roelfsema F, Schutte PJ, Smit JW, Romijn JA & Pereira AM 2007 The natural course of non-functioning pituitary macroadenomas. European Journal of Endocrinology 156 217–224.[Abstract/Free Full Text]

Ferone D, Arvigo M, Semino C, Jaquet P, Saveanu A, Taylor JE, Moreau JP, Culler MD, Albertelli M, Minuto F et al. 2005 Somatostatin and dopamine receptor expression in lung carcinoma cells and effects of chimeric somatostatin-dopamine molecules on cell proliferation. American Journal of Physiology. Endocrinology and Metabolism 289 E1044–E1050.[Abstract/Free Full Text]

Ferrante E, Ferraroni M, Castrignano T, Menicatti L, Anagni M, Reimondo G, Del Monte P, Bernasconi D, Loli P, Faustini-Fustini M et al. 2006 Non-functioning pituitary adenoma database: a useful resource to improve the clinical management of pituitary tumors. European Journal of Endocrinology 155 823–829.[Abstract/Free Full Text]

Florio T, Pan MG, Newman B, Hershberger RE, Civelli O & Stork PJ 1992 Dopaminergic inhibition of DNA synthesis in pituitary tumor cells is associated with phosphotyrosine phosphatase activity. Journal of Biological Chemistry 267 24169–24172.[Abstract/Free Full Text]

Florio T, Thellung S, Arena S, Corsaro A, Spaziante R, Gussoni G, Acuto G, Giusti M, Giordano G & Schettini G 1999 Somatostatin and its analog lanreotide inhibit the proliferation of dispersed human non-functioning pituitary adenoma cells in vitro. European Journal of Endocrinology 141 396–408.[Abstract]

Florio T, Arena S, Thellung S, Iuliano R, Corsaro A, Massa A, Pattarozzi A, Bajetto A, Trapasso F, Fusco A et al. 2001 The activation of the phosphotyrosine phosphatase {eta} (r-PTPh) is responsible for the somatostatin inhibition of PC Cl3 thyroid cell proliferation. Molecular Endocrinology 15 1838–1852.[Abstract/Free Full Text]

Gittoes NJ, Bates AS, Tse W, Bullivant B, Sheppard MC, Clayton RN & Stewart PM 1998 Radiotherapy for non-function pituitary tumours. Clinical Endocrinology 48 331–337.[CrossRef][Medline]

Greenman Y & Melmed S 1994a Expression of three somatostatin receptor subtypes in pituitary adenomas: evidence for preferential SSTR5 expression in the mammosomatotroph lineage. Journal of Clinical Endocrinology and Metabolism 79 724–729.[Abstract]

Greenman Y & Melmed S 1994b Heterogeneous expression of two somatostatin receptor subtypes in pituitary tumors. Journal of Clinical Endocrinology and Metabolism 78 398–403.[Abstract]

Greenman Y & Melmed S 1996 Diagnosis and management of nonfunctioning pituitary tumors. Annual Review of Medicine 47 95–106.[CrossRef][Web of Science][Medline]

Greenman Y, Ouaknine G, Veshchev I, Reider G II, Segev Y & Stern N 2003 Postoperative surveillance of clinically nonfunctioning pituitary macroadenomas: markers of tumour quiescence and regrowth. Clinical Endocrinology 58 763–769.[CrossRef][Medline]

Greenman Y, Tordjman K, Osher E, Veshchev I, Shenkerman G, Reider G II, Segev Y, Ouaknine G & Stern N 2005 Postoperative treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists decreases tumour remnant growth. Clinical Endocrinology 63 39–44.[CrossRef][Medline]

Gruszka A, Kunert-Radek J, Radek A, Pisarek H, Taylor J, Dong JZ, Culler MD & Pawlikowski M 2006 The effect of selective sst1, sst2, sst5 somatostatin receptors agonists, a somatostatin/dopamine (SST/DA) chimera and bromocriptine on the ‘clinically non-functioning’ pituitary adenomas in vitro. Life Science 78 689–693.[CrossRef][Web of Science][Medline]

Gruszka A, Ren SG, Dong J, Culler MD & Melmed S 2007 Regulation of growth hormone and prolactin gene expression and secretion by chimeric somatostatin-dopamine molecules. Endocrinology 148 6107–6114.[Abstract/Free Full Text]

Van Ham II, Banihashemi B, Wilson AM, Jacobsen KX, Czesak M & Albert PR 2007 Differential signaling of dopamine-D2S and -D2L receptors to inhibit ERK1/2 phosphorylation. Journal of Neurochemistry 102 1796–1804.[CrossRef][Web of Science][Medline]

de Herder WW, Reijs AE, Feelders RA, van Aken MO, Krenning EP, Tanghe HL, van der Lely AJ & Kwekkeboom DJ 2006 Dopamine agonist therapy of clinically non-functioning pituitary macroadenomas. Is there a role for 123I-epidepride dopamine D2 receptor imaging? European Journal of Endocrinology 155 717–723.[Abstract/Free Full Text]

Hofland LJ, De Herder WW, Visser-Wisselaar HA, Van Uffelen C, Waaijers M, Zuyderwijk J, Uitterlinden P, Kros MJ, Van Koetsveld PM & Lamberts SW 1997 Dissociation between the effects of somatostatin (SS) and octapeptide SS-analogs on hormone release in a small subgroup of pituitary- and islet cell tumors. Journal of Clinical Endocrinology and Metabolism 82 3011–3018.[Abstract/Free Full Text]

Hofland LJ, van der Hoek J, van Koetsveld PM, de Herder WW, Waaijers M, Sprij-Mooij D, Bruns C, Weckbecker G, Feelders R, van der Lely AJ et al. 2004 The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro. Journal of Clinical Endocrinology and Metabolism 89 1577–1585.[Abstract/Free Full Text]

Hofland LJ, van der Hoek J, Feelders R, van Aken MO, van Koetsveld PM, Waaijers M, Sprij-Mooij D, Bruns C, Weckbecker G, de Herder WW et al. 2005 The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. European Journal of Endocrinology 152 645–654.[Abstract/Free Full Text]

Iaccarino C, Samad TA, Mathis C, Kercret H, Picetti R & Borrelli E 2002 Control of lactotrop proliferation by dopamine: essential role of signaling through D2 receptors and ERKs. PNAS 99 14530–14535.[Abstract/Free Full Text]

Jaquet P, Ouafik L, Saveanu A, Gunz G, Fina F, Dufour H, Culler MD, Moreau JP & Enjalbert A 1999 Quantitative and functional expression of somatostatin receptor subtypes in human prolactinomas. Journal of Clinical Endocrinology and Metabolism 84 3268–3276.[Abstract/Free Full Text]

Jaquet P, Saveanu A, Gunz G, Fina F, Zamora AJ, Grino M, Culler MD, Moreau JP, Enjalbert A & Ouafik LH 2000 Human somatostatin receptor subtypes in acromegaly: distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes. Journal of Clinical Endocrinology and Metabolism 85 781–792.[Abstract/Free Full Text]

Jaquet P, Gunz G, Saveanu A, Dufour H, Taylor J, Dong J, Kim S, Moreau JP, Enjalbert A & Culler MD 2005 Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy. European Journal of Endocrinology 153 135–141.[Abstract/Free Full Text]

Katznelson L, Oppenheim DS, Coughlin JF, Kliman B, Schoenfeld DA & Klibanski A 1992 Chronic somatostatin analog administration in patients with alpha-subunit-secreting pituitary tumors. Journal of Clinical Endocrinology and Metabolism 75 1318–1325.[Abstract]

Klibanski A, Alexander JM, Bikkal HA, Hsu DW, Swearingen B & Zervas NT 1991 Somatostatin regulation of glycoprotein hormone and free subunit secretion in clinically nonfunctioning and somatotroph adenomas in vitro. Journal of Clinical Endocrinology and Metabolism 73 1248–1255.[Abstract/Free Full Text]

Kolch W, Heidecker G, Kochs G, Hummel R, Vahidi H, Mischak H, Finkenzeller G, Marme D & Rapp UR 1993 Protein kinase C alpha activates RAF-1 by direct phosphorylation. Nature 364 249–252.[CrossRef][Medline]

Kontogeorgos G 2005 Classification and pathology of pituitary tumors. Endocrine 28 27–35.[CrossRef][Medline]

Koper JW, Hofland LJ, van Koetsveld PM, den Holder F & Lamberts SW 1990 Desensitization and resensitization of rat pituitary tumor cells in long-term culture to the effects of the somatostatin analogue SMS 201-995 on cell growth and prolactin secretion. Cancer Research 50 6238–6242.[Abstract/Free Full Text]

Lania A, Filopanti M, Corbetta S, Losa M, Ballare E, Beck-Peccoz P & Spada A 2003 Effects of hypothalamic neuropeptides on extracellular signal-regulated kinase (ERK1 and ERK2) cascade in human tumoral pituitary cells. Journal of Clinical Endocrinology and Metabolism 88 1692–1696.[Abstract/Free Full Text]

Lohmann T, Trantakis C, Biesold M, Prothmann S, Guenzel S, Schober R & Paschke R 2001 Minor tumour shrinkage in nonfunctioning pituitary adenomas by long-term treatment with the dopamine agonist cabergoline. Pituitary 4 173–178.[CrossRef][Medline]

Lopez F, Esteve JP, Buscail L, Delesque N, Saint-Laurent N, Theveniau M, Nahmias C, Vaysse N & Susini C 1997 The tyrosine phosphatase SHP-1 associates with the sst2 somatostatin receptor and is an essential component of sst2-mediated inhibitory growth signaling. Journal of Biological Chemistry 272 24448–24454.[Abstract/Free Full Text]

Mantovani G, Bondioni S, Ferrero S, Gamba B, Ferrante E, Peverelli E, Corbetta S, Locatelli M, Rampini P, Beck-Peccoz P et al. 2005 Effect of cyclic adenosine 3',5'-monophosphate/protein kinase a pathway on markers of cell proliferation in nonfunctioning pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 90 6721–6724.[Abstract/Free Full Text]

Massa A, Barbieri F, Aiello C, Arena S, Pattarozzi A, Pirani P, Corsaro A, Iuliano R, Fusco A, Zona G et al. 2004 The expression of the phosphotyrosine phosphatase DEP-1/PTP{eta} dictates the responsivity of glioma cells to somatostatin inhibition of cell proliferation. Journal of Biological Chemistry 279 29004–29012.[Abstract/Free Full Text]

Nielsen S, Mellemkjaer S, Rasmussen LM, Ledet T, Olsen N, Bojsen-Moller M, Astrup J, Weeke J & Jorgensen JO 2001 Expression of somatostatin receptors on human pituitary adenomas in vivo and ex vivo. Journal of Endocrinological Investigation 24 430–437.[Web of Science][Medline]

Pan MG, Florio T & Stork PJ 1992 G protein activation of a hormone-stimulated phosphatase in human tumor cells. Science 256 1215–1217.[Abstract/Free Full Text]

Pawlikowski M, Pisarek H, Kunert-Radek J & Radek A 2003 Immunohistochemical detection of somatostatin receptor subtypes in ‘clinically nonfunctioning’ pituitary adenomas. Endocrine Pathology 14 231–238.[CrossRef][Web of Science][Medline]

Pellegrini I, Rasolonjanahary R, Gunz G, Bertrand P, Delivet S, Jedynak CP, Kordon C, Peillon F, Jaquet P & Enjalbert A 1989 Resistance to bromocriptine in prolactinomas. Journal of Clinical Endocrinology and Metabolism 69 500–509.[Abstract/Free Full Text]

Pivonello R, Ferone D, de Herder WW, de Krijger RR, Waaijers M, Mooij DM, van Koetsveld PM, Barreca A, De Caro ML, Lombardi G et al. 2004 Dopamine receptor expression and function in human normal adrenal gland and adrenal tumors. Journal of Clinical Endocrinology and Metabolism 89 4493–4502.[Abstract/Free Full Text]

Pivonello R, Ferone D, de Herder WW, Faggiano A, Bodei L, de Krijger RR, Lombardi G, Colao A, Lamberts SW & Hofland LJ 2007 Dopamine receptor expression and function in corticotroph ectopic tumors. Journal of Clinical Endocrinology and Metabolism 92 65–69.[Abstract/Free Full Text]

Plockinger U, Reichel M, Fett U, Saeger W & Quabbe HJ 1994 Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy. Journal of Clinical Endocrinology and Metabolism 79 1416–1423.[Abstract]

Renner U, Mojto J, Lange M, Muller OA, von Werder K & Stalla GK 1994 Effect of bromocriptine and SMS 201-995 on growth of human somatotrophic and non-functioning pituitary adenoma cells in vitro. European Journal of Endocrinology 130 80–91.[Abstract/Free Full Text]

Renner U, Arzberger T, Pagotto U, Leimgruber S, Uhl E, Muller A, Lange M, Weindl A & Stalla GK 1998 Heterogeneous dopamine D2 receptor subtype messenger ribonucleic acid expression in clinically nonfunctioning pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 83 1368–1375.[Abstract/Free Full Text]

Reubi JC, Waser B, Schaer JC & Laissue JA 2001 Somatostatin receptor sst1–sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. European Journal of Nuclear Medicine 28 836–846.[CrossRef][Web of Science][Medline]

Rocheville M, Lange DC, Kumar U, Patel SC, Patel RC & Patel YC 2000 Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science 288 154–157.[Abstract/Free Full Text]

Saveanu A, Morange-Ramos I, Gunz G, Dufour H, Enjalbert A & Jaquet P 2001 A luteinizing hormone-, alpha-subunit- and prolactin-secreting pituitary adenoma responsive to somatostatin analogs: in vivo and in vitro studies. European Journal of Endocrinology 145 35–41.[Abstract]

Saveanu A, Lavaque E, Gunz G, Barlier A, Kim S, Taylor JE, Culler MD, Enjalbert A & Jaquet P 2002 Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells. Journal of Clinical Endocrinology and Metabolism 87 5545–5552.[Abstract/Free Full Text]

van Schaardenburg D, Roelfsema F, van Seters AP & Vielvoye GJ 1989 Bromocriptine therapy for non-functioning pituitary adenoma. Clinical Endocrinology 30 475–484.[Medline]

Taboada GF, Luque RM, Bastos W, Guimaraes RF, Marcondes JB, Chimelli LM, Fontes R, Mata PJ, Filho PN, Carvalho DP et al. 2007 Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas. European Journal of Endocrinology 156 65–74.[Abstract/Free Full Text]

Warnet A, Harris AG, Renard E, Martin D, James-Deidier A & Chaumet-Riffaud P 1997 A prospective multicenter trial of octreotide in 24 patients with visual defects caused by nonfunctioning and gonadotropin-secreting pituitary adenomas. French Multicenter Octreotide Study Group. Neurosurgery 41 786–796.[CrossRef][Web of Science][Medline]

Zatelli MC, Piccin D, Bottoni A, Ambrosio MR, Margutti A, Padovani R, Scanarini M, Taylor JE, Culler MD, Cavazzini L et al. 2004 Evidence for differential effects of selective somatostatin receptor subtype agonists on alpha-subunit and chromogranin a secretion and on cell viability in human nonfunctioning pituitary adenomas in vitro. Journal of Clinical Endocrinology and Metabolism 89 5181–5188.[Abstract/Free Full Text]




This article has been cited by other articles:


Home page
 J Mol EndocrinolHome page
D. Ferone, F. Gatto, M. Arvigo, E. Resmini, M. Boschetti, C. Teti, D. Esposito, and F. Minuto
The clinical-molecular interface of somatostatin, dopamine and their receptors in pituitary pathophysiology
J. Mol. Endocrinol., May 1, 2009; 42(5): 361 - 370.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
A. Colao, C. Di Somma, R. Pivonello, A. Faggiano, G. Lombardi, and S. Savastano
Medical therapy for clinically non-functioning pituitary adenomas
Endocr. Relat. Cancer, December 1, 2008; 15(4): 905 - 915.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. Barbieri, A. Bajetto, R. Stumm, A. Pattarozzi, C. Porcile, G. Zona, A. Dorcaratto, J.-L. Ravetti, F. Minuto, R. Spaziante, et al.
Overexpression of Stromal Cell-Derived Factor 1 and Its Receptor CXCR4 Induces Autocrine/Paracrine Cell Proliferation in Human Pituitary Adenomas
Clin. Cancer Res., August 15, 2008; 14(16): 5022 - 5032.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Florio, T.
Right arrow Articles by Jaquet, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Florio, T.
Right arrow Articles by Jaquet, P.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS